Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2023)

Inhibikase Therapeutics (IKT) has 4 years of EBT Margin data on record, last reported at 440356600.0% in Q4 2023.

  • On a quarterly basis, EBT Margin fell 44034978036.0% to 440356600.0% in Q4 2023 year-over-year; TTM through Sep 2024 was 2006393700.0%, a 200638752188.0% decrease, with the full-year FY2023 number at 7711.98%, up 697419.0% from a year prior.
  • EBT Margin reached 440356600.0% in Q4 2023 per IKT's latest filing, down from 5993.38% in the prior quarter.
  • Over the last five years, EBT Margin for IKT hit a ceiling of 187.4% in Q1 2021 and a floor of 440356600.0% in Q4 2023.
  • A 4-year average of 27549285.01% and a median of 5660.72% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 25252290bps in 2022, then crashed 2000000000bps in 2023.
  • Tracing IKT's EBT Margin over 4 years: stood at 708.85% in 2020, then tumbled by -36487bps to 259342.54% in 2021, then skyrocketed by 97bps to 6819.64% in 2022, then tumbled by -6457080bps to 440356600.0% in 2023.
  • Business Quant data shows EBT Margin for IKT at 440356600.0% in Q4 2023, 5993.38% in Q3 2023, and 5328.07% in Q2 2023.